Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
184M
-
Shares change
-
-13.3M
-
Total reported value, excl. options
-
$208M
-
Value change
-
-$15.4M
-
Put/Call ratio
-
0.66
-
Number of buys
-
68
-
Number of sells
-
-70
-
Price
-
$1.13
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q2 2025
185 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q2 2025.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 184M shares
of 226M outstanding shares and own 81.17% of the company stock.
Largest 10 shareholders include Pfizer Inc (22M shares), TPG GP A, LLC (18.7M shares), BlackRock, Inc. (17.9M shares), Capital World Investors (11.2M shares), Lynx1 Capital Management LP (11.1M shares), Darwin Global Management, Ltd. (10.5M shares), CITADEL ADVISORS LLC (10.3M shares), VANGUARD GROUP INC (8.26M shares), PRIMECAP MANAGEMENT CO/CA/ (5.72M shares), and GOLDMAN SACHS GROUP INC (5.5M shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.